19.45
1.30%
+0.25
After Hours:
19.45
Veracyte Inc stock is currently priced at $19.45, with a 24-hour trading volume of 908.50K.
It has seen a +1.30% increased in the last 24 hours and a -10.24% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $19.05 pivot point. If it approaches the $19.50 resistance level, significant changes may occur.
Veracyte Inc Stock (VCYT) Financials Data
Veracyte Inc (VCYT) Revenue 2024
VCYT reported a revenue (TTM) of $361.05 million for the quarter ending December 31, 2023, a +21.76% rise year-over-year.
Veracyte Inc (VCYT) Net Income 2024
VCYT net income (TTM) was -$74.40 million for the quarter ending December 31, 2023, a -103.51% decrease year-over-year.
Veracyte Inc (VCYT) Cash Flow 2024
VCYT recorded a free cash flow (TTM) of $34.26 million for the quarter ending December 31, 2023, a +3,479% increase year-over-year.
Veracyte Inc (VCYT) Earnings per Share 2024
VCYT earnings per share (TTM) was -$1.03 for the quarter ending December 31, 2023, a -106.00% decline year-over-year.
Veracyte Inc Stock (VCYT) Latest News
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Seeking Alpha
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
Benzinga
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
Benzinga
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Benzinga
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
Zacks Investment Research
Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
About Veracyte Inc
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):